低浓度平阳霉素联合地塞米松硬化治疗唇部浅表静脉畸形

Percutaneous sclerotherapy for superficial venous malformations of the lips with low concentration Pingyangmycin and dexamethasonum

目的:观察低浓度平阳霉素加地塞米松硬化治疗唇部浅表静脉畸形的临床疗效。方法:2007年1月～2011年1月,笔者科室应用低浓度平阳霉素(0.5mg/ml)联合地塞米松(1mg/ml)硬化治疗唇部浅表静脉畸形患者68例,其中男29例,女39例,年龄13～69岁;病变范围最小0.5cm×0.8cm,最大3cm×2.4cm。根据病变情况决定治疗的次数,2次治疗间隔15天。结果:68例患者最少注射2次,最多注射8次,治疗后随访12～32个月,平均随访21个月。患者外观满意,没有复发倾向。根据疗效评价标准,治愈66例,有效2例。结论:低浓度平阳霉素联合地塞米松硬化治疗唇部浅表静脉畸形是一种安全、有效的治疗方法。

Objective To evaluate the clinical effect of using low concentration Pingyangmycin and dexamethasonum to treat superficial vascular malformation of the lips. Methods Sixty eight patients with superficial venous malformation of the lips （29 males and 39 females, age range：13-69 years）were treated in our department from January 2007 to January 2011.The lesions ranged in size from 0.5cm x0.8cm to 3cm x2.1cm. Pingyangmycin （about 0.5mg/ml）and dexamethasonum （about lmg/ml） was injected into the center and periphery of the superficial venous malformation, the injection was repeated every 15 days when necessary. Results All patients required multiple therapeutic sessions. At a mean follow-up of 21 months （range 12 to 32）, 66 patients were cured and 2 had marked improvement. No patients presented with signs of recurrence. Conclusion Percutaneous Sclerotherapy with low concentration Pingyangmycin and dexamethasonum is proved to be a safe, effective therapy for superficial venous malformations of the lips.